A5009903748- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Renal and related cancers
- Economic and Financial Impacts of Cancer
- Bone health and treatments
- COVID-19 and healthcare impacts
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- COVID-19 Clinical Research Studies
- Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Corneal Surgery and Treatments
- Urinary and Genital Oncology Studies
- melanin and skin pigmentation
- Flavonoids in Medical Research
- Oral health in cancer treatment
- Infection Control and Ventilation
- Radiomics and Machine Learning in Medical Imaging
- Nonmelanoma Skin Cancer Studies
Ospedale Papa Giovanni XXIII
2016-2025
University of Pavia
2007
Istituti di Ricovero e Cura a Carattere Scientifico
2007
Policlinico San Matteo Fondazione
1994-2005
// Mirko Marabese 1,* , Monica Ganzinelli 2,* Marina C. Garassino 2 Frances A. Shepherd 3 Sheila Piva 4 Elisa Caiola 1 Marianna Macerelli Anna Bettini 5 Calogero Lauricella 6 Irene Floriani Gabriella Farina Flavia Longo 7 Lucia Bonomi M. Agnese Fabbri 8 Silvio Veronese Silvia Marsoni 9 Massimo Broggini and Eliana Rulli Oncology Department, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Fondazione Nazionale dei Tumori, Princess Margaret Cancer Center, University of...
Combinations of VEGFR-TKIs plus ICI against PD1/PD-L1 are the standard first-line therapy for patients with mRCC, irrespective prognostic class. This study aims to investigate feasibility and safety withdrawing VEGFR-TKI but continuing anti- in who achieve response their combination.
Background In ambulatory patients with cancer asymptomatic or pauci-symptomatic SARS-CoV-2 infection, the safety of targeted therapies (TTs), chemotherapy (CT) immune checkpoint inhibitors (ICIs) therapy is still unknown. Material and methods From start first epidemic wave in Bergamo, Italy, we have prospectively screened all consecutive outpatients who presented for treatment to Oncology Division Papa Giovanni XXIII Hospital, Bergamo antigen expression. We identified treated ICIs compared...
495 Background: Immune-combinations have become the cornerstone of mRCC treatment landscape, but head-to-head comparisons between different first-line strategies are lacking and few real-world data available in this setting. In context, little evidence is available, especially for IMDC poor-risk patients, who worst prognosis lowest response to standard treatments. Methods: The Meet-URO 33 study an Italian retrospective/prospective registry setting patients from January 2021 (Trial...
584 Background: KIM-1 was evaluated as plasma circulating biomarker of microscopical residual disease, disease recurrence after nephrectomy, and potential benefit from adjuvant immunotherapy (IO). No data are available about its role in the metastatic setting. Tide-A is a phase 2 trial showing feasibility de-intensified strategy VEGFR-TKI interruption IO-maintenance mRCC pts treated with ave+axi. We investigated whether prognostic prospective cohort Tide-A. Methods: Treatment-naïve prior no...
551 Background: Combinations of therapies with VEGFR-TKI (TKI) and anti-PD1/PDL1 immunotherapy (IO) are considered the standard care for first line treatment patients (pts) mRCC. The Tide-A trial previously reported feasibility TKI interruption maintenance in pts achieving tumor response after TKI+IO combination, its primary endpoint. Here we updated results a longer follow-up. Methods: Pts surgery tumor, without symptomatic/bulky disease or liver mets, were treated Ave 800 mg flat dose IV...
The prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated.We retrospectively evaluated the data NSCLC metastases TKIs 12 Italian centers from 2014 to 2019, primary aim explore type and frequency SREs.Seventy-seven out 274 enrolled (28%) developed at least one major SRE: 55/274 (20%) fractures, 30/274 (11%) spinal cord compression,...
This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib second line treatment not selected mRCC patients. 148 patients were evaluated. According to Heng score 15.5%, 60.1% 24.4% at poor risk, intermediate favorable respectively. PFS, OS, DCR ORR 7.14 months, 15.5 70.6% 16.6%, The duration prior sunitinib correlated with a longer significant mPFS, 8.8 vs 6.3 therapy safe, without grade 4 adverse events. most...
TPS495 Background: Radical metastasectomy and other local treatment strategies (including definitive radiotherapy, RT) can be carried out instead of systemic therapies for selected metastatic renal cell carcinoma (mRCC) patients (pts) with the aim healing patient even in an advanced disease stage. Recent data suggests a potential benefit from perioperative immunotherapy immune checkpoint inhibitors (ICIs), as shown by significant efficacy adjuvant pembrolizumab M1 NED subgroup KEYNOTE-564...
In Europe, the SARS-CoV-2 pandemic had its first epicenter in Italy. Despite a significant mortality rate, severity of most cases COVID-19 infection ranges from asymptomatic to mildly symptomatic, and silent affects still-unknown proportion general population. No information is available on prevalence clinical impact among patients with cancer receiving anticancer treatment during pandemic.
Background: Meningeal carcinomatosis is rare in patients with kidney cancer and treatment options are limited. Few treated systemic approaches have been reported. We describe a case of complete remission leptomeningeal metastasis patient renal cell carcinoma nivolumab. To our knowledge, this the first report nivolumab safety efficacy particular site metastasis. Case presentation: Our was 60-year-old Caucasian man bone lung metastases from carcinoma. He developed progression lesions after...
Single nucleotide polymorphisms (SNPs) in the DNA repair genes are believed to contribute clinical outcome of patients receiving platinum-based chemotherapy. We investigated impact 2 SNPs excision cross-complementation group 1 and xeroderma pigmentosum complementation G on with non-small-cell lung cancer (NSCLC) treated chemotherapy.Between October 2007 March 2012, we collected 374 blood samples from consecutive registered TAILOR trial. Four (rs11615, rs3212986, rs17655, rs1047768) were...